关键字不能为空!

Enter

Home » Patient Care » Departments & Services » Institutes » Peking University Hepatology Institute

Peking University Hepatology Institute

Peking University Hepatology Institute


    Peking University Hepatology Institute (PUHI), the first institute for viral hepatitis in China, was established in 1978. We have made historic contributions to the prevention and treatment of viral hepatitis in China by developing the firs tHBV vaccine and first generation of HBV and HCV diagnostic agent. PUHI have received more than eighty awards, including one 1st prize, three 2nd prizes and one 3rd Prize National Science and Technology Progress Award from the Ministry of Science and Technology.


    PUHI, now led by professor Lai Wei, grew out of Being Medical School People’s Hospital Hepatology Institute and, through 40 years of development, have grew to become a comprehensive institute, including Research Institute, Department of Hepatology, Department of Infectious Disease, Clinical Lab and Post-Doctoral Research Center of Peking University. For our pioneering work in the treatment and study of liver and infectious diseases, PUHI was awarded the Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, a Clinical Pharmacology Research centers by the Ministry of Health and SFDA of PRC, and a National Key Clinical Specialty of Infectious Disease. For the commitment in clinical laboratory ever since its establishment, the Clinical Lab of PUHI passed the Laboratory Accreditation Programme held by CAP (College of American Pathologists) and CNAS (China National Accreditation Service for Conformity Assessment), and participated in the China’s national laboratory network for infectious disease.


    PUHI led or undertake a large number of National Key S & T Projects since the "6th Five-Year Plan" of China, and participate in up to six and seven projects during the “11th and 12th Five-Year Plan”, respectively. PUHI is committed to advancing research in areas including: (1) Hepatitis C: molecular virology, prognosis of HCV infection & optimizing treatment for difficult-to-treat Hepatitis C; (2) Hepatitis B: Immunology interactions between virus and hepatocytes, antiviral therapy; (3) Hepatocellular carcinoma: the mechanism of HCC pathogenesis, metastasis and recurrence, immunotherapy of HCC; (4) Liver failure- Diagnosis and Mechanism; (5) Fatty liver- epidemiology, diagnosis and mechanism study. PUHI have also established international collaborations with colleagues around the world, including University of Michigan (United States), Drexel university, and Agency for Science, Technology and Research (A*STAR, Singapore).